On September 28th, ASBM Advisory Board Chair Philip Schneider presented an online Continuing Education (CE) course entitled the “The State of the Biosimilars Market in 2021”. The course was presented in conjunction with Long Island University College of Pharmacy and is the third in the series “Biosimilars: What Pharmacists Need to Know”. The series is accredited by the American Council on Pharmaceutical Education (ACPE).
In the presentation, Dr. Schneider discussed the potential economic benefits of biosimilars, and examined different approaches countries around the world have used for driving their uptake. While some countries experimented with forced substitution of government-preferred products, those with the most successful biosimilars markets permitted physicians to retain control over prescribing decisions. These countries achieved savings through the increased competition of many products being freely available and reimbursed by payers.
Dr. Schneider also discussed patient and physician concerns with the non-medical switching of patients who are stable on their current therapies; and how the U.S. interchangeability standard addresses these concerns.
View the latest course here.
View the first course in the series here: “Biosimilars: What Pharmacists Need to Know”.
View the second course in the series here: “Substitution and Non-Medical Switching”